These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. De Stefano N; Comi G; Kappos L; Freedman MS; Polman CH; Uitdehaag BM; Hennessy B; Casset-Semanaz F; Lehr L; Stubinski B; Jack DL; Barkhof F J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):647-53. PubMed ID: 24292999 [TBL] [Abstract][Full Text] [Related]
7. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Kappos L; Polman CH; Freedman MS; Edan G; Hartung HP; Miller DH; Montalban X; Barkhof F; Bauer L; Jakobs P; Pohl C; Sandbrink R Neurology; 2006 Oct; 67(7):1242-9. PubMed ID: 16914693 [TBL] [Abstract][Full Text] [Related]
8. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. Miller DH; Molyneux PD; Barker GJ; MacManus DG; Moseley IF; Wagner K Ann Neurol; 1999 Dec; 46(6):850-9. PubMed ID: 10589537 [TBL] [Abstract][Full Text] [Related]
9. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409 [TBL] [Abstract][Full Text] [Related]
10. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466 [TBL] [Abstract][Full Text] [Related]
11. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. Jacobs LD; Beck RW; Simon JH; Kinkel RP; Brownscheidle CM; Murray TJ; Simonian NA; Slasor PJ; Sandrock AW N Engl J Med; 2000 Sep; 343(13):898-904. PubMed ID: 11006365 [TBL] [Abstract][Full Text] [Related]
12. Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. Polman C; Kappos L; Freedman MS; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Selmaj K; Uitdehaag BM; Dahms S; Bauer L; Pohl C; Sandbrink R; J Neurol; 2008 Apr; 255(4):480-7. PubMed ID: 18004635 [TBL] [Abstract][Full Text] [Related]
13. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Comi G; Filippi M; Barkhof F; Durelli L; Edan G; Fernández O; Hartung H; Seeldrayers P; Sørensen PS; Rovaris M; Martinelli V; Hommes OR; Lancet; 2001 May; 357(9268):1576-82. PubMed ID: 11377645 [TBL] [Abstract][Full Text] [Related]
14. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW; Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990 [TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. Moraal B; Pohl C; Uitdehaag BM; Polman CH; Edan G; Freedman MS; Hartung HP; Kappos L; Miller DH; Montalban X; Lanius V; Sandbrink R; Barkhof F Arch Neurol; 2009 Nov; 66(11):1345-52. PubMed ID: 19901165 [TBL] [Abstract][Full Text] [Related]
16. Interferon-β-1b: a review of its use in multiple sclerosis. Plosker GL CNS Drugs; 2011 Jan; 25(1):67-88. PubMed ID: 21128695 [TBL] [Abstract][Full Text] [Related]
17. Interferon-beta-1b: in newly emerging multiple sclerosis. McKeage K CNS Drugs; 2008; 22(9):787-92. PubMed ID: 18698876 [TBL] [Abstract][Full Text] [Related]
18. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. Soilu-Hänninen M; Aivo J; Lindström BM; Elovaara I; Sumelahti ML; Färkkilä M; Tienari P; Atula S; Sarasoja T; Herrala L; Keskinarkaus I; Kruger J; Kallio T; Rocca MA; Filippi M J Neurol Neurosurg Psychiatry; 2012 May; 83(5):565-71. PubMed ID: 22362918 [TBL] [Abstract][Full Text] [Related]